Pfizer's Sutent, Novartis' Afinitor Earn ODAC Backing For Pancreatic Tumors

Oncologic Drugs Advisory Committee's enthusiasm for sunitinib was tempered by complexities resulting from the pivotal trial's early termination, and the panel urged that everolimus only be used for patients with aggressive disease.